Table 1. Differential analysis of AML... | American Society of Hematology

Table 1.

Differential analysis of AML patient sample sensitivity to individual drugs in HS-5 CM or standard MCM

Drug name	Mechanism/targets	Included pairs	Mean DSS CM	Mean DSS MCM	Mean DSS difference	FDR
Ruxolitinib	JAK1/2	18	13.01	5.72	7.29	0.008
Docetaxel	Tubulin stabilizer	18	13.88	8.95	4.93	0.033
Tofacitinib	JAK2/3	18	4.94	1.04	3.91	0.003
AZD1480	JAK1/2, FGFR	18	5.83	2.31	3.53	0.035
Momelotinib	JAK1/2	18	13.91	11.20	2.71	0.033
Doxorubicin	Topoisomerase II	17	5.36	7.54	−2.18	0.047
Nutlin-3	Mdm-2	18	2.99	5.21	−2.22	0.021
Chloroquine	Antimalaria	18	7.63	9.85	−2.22	0.035
Canertinib	pan-ErbB	18	7.86	10.09	−2.23	0.014
Belinostat	HDAC	18	16.87	19.15	−2.28	0.049
Fludarabine	Purine analog	17	7.53	9.86	−2.33	0.020
Etoposide	Topoisomerase II	17	2.12	4.64	−2.52	0.033
Panobinostat	HDAC	18	20.33	22.93	−2.59	0.026
UNC0642	G9a/GLP	17	2.92	5.95	−3.03	0.026
Amonafide	Topoisomerase II	18	3.08	6.73	−3.66	0.004
AZ3146	Mps1	18	1.56	5.27	−3.71	0.026
Pictilisib	PI3K	18	7.82	11.65	−3.83	0.033
Mitoxantrone	Topoisomerase II	17	2.67	6.67	−4.00	0.026
Daunorubicin	Topoisomerase II	17	7.56	11.61	−4.05	0.003
Teniposide	Topoisomerase II	17	9.63	14.13	−4.50	0.047
Quisinostat	HDAC	18	16.90	21.66	−4.76	0.003
Navitoclax	BCL2/BCLXL	18	16.92	22.00	−5.08	0.020
Omacetaxine	Protein synthesis inhibitor	18	25.11	30.23	−5.13	0.000
Cabozantinib	VEGFR2, MET, FLT3, TIE2, KIT, RET	18	0.92	6.11	−5.19	0.033
Valrubicin	Topoisomerase II	17	8.06	13.29	−5.23	0.003
Idarubicin	Topoisomerase II	18	10.53	15.79	−5.26	0.026
AZD7762	CHK1/2	18	5.27	12.31	−7.04	0.035
Sunitinib	Broad TK inhibitor	18	2.26	9.69	−7.44	0.026
Ponatinib	Broad TK inhibitor	18	5.16	12.66	−7.50	0.033
Quizartinib	FLT3	18	0.79	8.47	−7.67	0.035
Foretinib	Broad TK inhibitor	18	2.93	10.83	−7.90	0.033
Venetoclax	BCL2	17	7.78	17.31	−9.52	0.008

Drug name	Mechanism/targets	Included pairs	Mean DSS CM	Mean DSS MCM	Mean DSS difference	FDR
Ruxolitinib	JAK1/2	18	13.01	5.72	7.29	0.008
Docetaxel	Tubulin stabilizer	18	13.88	8.95	4.93	0.033
Tofacitinib	JAK2/3	18	4.94	1.04	3.91	0.003
AZD1480	JAK1/2, FGFR	18	5.83	2.31	3.53	0.035
Momelotinib	JAK1/2	18	13.91	11.20	2.71	0.033
Doxorubicin	Topoisomerase II	17	5.36	7.54	−2.18	0.047
Nutlin-3	Mdm-2	18	2.99	5.21	−2.22	0.021
Chloroquine	Antimalaria	18	7.63	9.85	−2.22	0.035
Canertinib	pan-ErbB	18	7.86	10.09	−2.23	0.014
Belinostat	HDAC	18	16.87	19.15	−2.28	0.049
Fludarabine	Purine analog	17	7.53	9.86	−2.33	0.020
Etoposide	Topoisomerase II	17	2.12	4.64	−2.52	0.033
Panobinostat	HDAC	18	20.33	22.93	−2.59	0.026
UNC0642	G9a/GLP	17	2.92	5.95	−3.03	0.026
Amonafide	Topoisomerase II	18	3.08	6.73	−3.66	0.004
AZ3146	Mps1	18	1.56	5.27	−3.71	0.026
Pictilisib	PI3K	18	7.82	11.65	−3.83	0.033
Mitoxantrone	Topoisomerase II	17	2.67	6.67	−4.00	0.026
Daunorubicin	Topoisomerase II	17	7.56	11.61	−4.05	0.003
Teniposide	Topoisomerase II	17	9.63	14.13	−4.50	0.047
Quisinostat	HDAC	18	16.90	21.66	−4.76	0.003
Navitoclax	BCL2/BCLXL	18	16.92	22.00	−5.08	0.020
Omacetaxine	Protein synthesis inhibitor	18	25.11	30.23	−5.13	0.000
Cabozantinib	VEGFR2, MET, FLT3, TIE2, KIT, RET	18	0.92	6.11	−5.19	0.033
Valrubicin	Topoisomerase II	17	8.06	13.29	−5.23	0.003
Idarubicin	Topoisomerase II	18	10.53	15.79	−5.26	0.026
AZD7762	CHK1/2	18	5.27	12.31	−7.04	0.035
Sunitinib	Broad TK inhibitor	18	2.26	9.69	−7.44	0.026
Ponatinib	Broad TK inhibitor	18	5.16	12.66	−7.50	0.033
Quizartinib	FLT3	18	0.79	8.47	−7.67	0.035
Foretinib	Broad TK inhibitor	18	2.93	10.83	−7.90	0.033
Venetoclax	BCL2	17	7.78	17.31	−9.52	0.008

False discovery rate, FDR < 0.05.